TY - JOUR
T1 - Carbohydrate restriction in patients with advanced cancer
T2 - A protocol to assess safety and feasibility with an accompanying hypothesis
AU - Fine, Eugene J.
AU - Segal-Isaacson, C. J.
AU - Feinman, Richard
AU - Sparano, Joseph
PY - 2008/1
Y1 - 2008/1
N2 - Dietary carbohydrate restriction provokes systemic metabolic and cell signaling effects including down-regulation of insulin, insulin-like growth factors, fatty acid synthase, and other enzymatic and signaling targets. These effects as well as increased availability of fatty acids and ketone bodies may plausibly inhibit aggressive glycolytic cancers. We have designed a 28-day clinical trial diet of very low carbohydrate intake under nutritionist guidance to test the safety and feasibility in patients with advanced glucose-dependent solid cancers, determined by a positive baseline positron emission tomography (PET) scan using 18-fluorodeoxyglucose to demonstrate glucose avidity. Changes in a follow-up PET scan at study's end permit a surrogate measure of efficacy.
AB - Dietary carbohydrate restriction provokes systemic metabolic and cell signaling effects including down-regulation of insulin, insulin-like growth factors, fatty acid synthase, and other enzymatic and signaling targets. These effects as well as increased availability of fatty acids and ketone bodies may plausibly inhibit aggressive glycolytic cancers. We have designed a 28-day clinical trial diet of very low carbohydrate intake under nutritionist guidance to test the safety and feasibility in patients with advanced glucose-dependent solid cancers, determined by a positive baseline positron emission tomography (PET) scan using 18-fluorodeoxyglucose to demonstrate glucose avidity. Changes in a follow-up PET scan at study's end permit a surrogate measure of efficacy.
UR - http://www.scopus.com/inward/record.url?scp=38949193472&partnerID=8YFLogxK
U2 - 10.1016/S1548-5315(11)70179-6
DO - 10.1016/S1548-5315(11)70179-6
M3 - Article
AN - SCOPUS:38949193472
SN - 1548-5315
VL - 5
SP - 22
EP - 26
JO - Community Oncology
JF - Community Oncology
IS - 1
ER -